Munatrep 5 Mg / 25 Mg / 50 Mg / 100 Mg / 200 Mg Tablets 5 mg / 25 mg / 50 mg / 100 mg / 200 mg TABLET
PDF Leaflet Revision Date: 13 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Monotherapy or add-on treatment for epilepsy and bipolar disorder.
Dosage (summary)
Adults: Initial 25 mg daily, increase to 100-200 mg. Children: 0.6 mg/kg/day, max 400 mg.
Onset of Action / Duration
Onset: 1.4 to 4.8 hours, Duration: 25 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- Valproic acid increases half-life
- Enzyme inducers decrease half-life
Contraindications
- Hypersensitivity to lamotrigine
- Severe renal or hepatic impairment
- Pregnancy and lactation
Common side effects
- Headache
- Dizziness
- Skin rash
- Nausea
- Drowsiness
Counselling Points
- Report any rash or flu-like symptoms immediately.
- Avoid driving until effects are known.
- Monitor weight in children for dosage adjustments.
Serious warnings
- Risk of severe skin reactions
- Monitor for hypersensitivity symptoms
- Risk of seizures on abrupt withdrawal
Important Disclaimer
The Munatrep 5 Mg / 25 Mg / 50 Mg / 100 Mg / 200 Mg Tablets 5 mg / 25 mg / 50 mg / 100 mg / 200 mg TABLET professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
